Long-term safety of extended-release oxybutynin chloride in a community-dwelling population of participants with overactive bladder: a one-year study.
In this multicenter, open-label study of extended- and immediate-release oxybutynin chloride, community-dwelling participants were studied for up to 12 months to evaluate the long-term safety profile of extended-release oxybutynin. Quality-of-life assessments designed to measure the impact of incontinence and evaluate treatment outcome were used to study subjective improvement. A total of 904 women and 163 men (mean age 64 years, range 29-91 years) were enrolled. The majority of discontinuations were in the first 3 months (25.5%); of those who continued after 3 months, 62% remained on extended-release oxybutynin chloride for one year. The majority of discontinuations were for adverse events; dry mouth was the most frequently cited event leading to discontinuation (8.4%). Significant improvements were seen in QOL measures. Long-term therapy with extended-release oxybutynin chloride was generally well tolerated and effective, improving quality of life significantly in participants with overactive bladder over 3-12 months of therapy.
Diokno
Ananias
A
William Beaumont Hospital, Royal Oak, MI 48073, USA.
Sand
Peter
P
Labasky
Richard
R
Sieber
Paul
P
Antoci
Joseph
J
Leach
Gary
G
Atkinson
Linda
L
Albrecht
Detlef
D
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018680:Cholinergic Antagonists / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D005260:Female; D006801:Humans; D008297:Male; D008333:Mandelic Acids / Q000627:therapeutic use*; D008875:Middle Aged; D012111:Residence Characteristics; D013997:Time Factors; D014481:United States; D014549:Urinary Incontinence / Q000188:drug therapy*; D014987:Xerostomia / Q000517:prevention & control*
D018680:Cholinergic Antagonists; D003692:Delayed-Action Preparations; D008333:Mandelic Acids; C005419:oxybutynin